TRIESENCE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRIESENCE (TRIESENCE).
Corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating cytokine production.
| Metabolism | Hepatic via CYP3A4; primary metabolites include 6β-hydroxycorticosteroids. |
| Excretion | Primarily hepatic metabolism; renal excretion of metabolites (<5% unchanged). Biliary/fecal elimination accounts for minimal clearance. |
| Half-life | Approximately 3.3 hours for triamcinolone acetonide; with intravitreal administration, detectable levels persist for weeks to months. |
| Protein binding | 68% bound to corticosteroid-binding globulin (CBG) and albumin. |
| Volume of Distribution | 0.57 L/kg; indicates distribution into total body water and peripheral tissues. |
| Bioavailability | Intravitreal: 100% (local); intramuscular: ~70-100% after absorption; oral: ~23% (due to first-pass metabolism); topical: minimal systemic absorption. |
| Onset of Action | Intravitreal: 1-2 days; intramuscular: 24-48 hours; intra-articular: 12-24 hours; topical: variable (hours to days). |
| Duration of Action | Intravitreal: weeks to months (sustained release); intramuscular: 2-3 weeks; intra-articular: 1-2 weeks; topical: days. |
| Molecular Weight | 434.5 |
1 to 4 mg (0.025 to 0.1 mL of 40 mg/mL suspension) intravitreal injection once.
| Dosage form | INJECTABLE |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No specific guidelines; use with caution in severe hepatic impairment. |
| Pediatric use | Not established; safety and efficacy in pediatric patients have not been determined. |
| Geriatric use | No specific dose adjustments; use with caution due to potential increased sensitivity. |
| 1st trimester | Corticosteroids are teratogenic in animal studies; however, data in humans suggest low risk for oral clefts when used in first trimester. Use only if clearly needed. |
| 2nd trimester | May increase risk of intrauterine growth restriction (IUGR) with prolonged use. Monitor fetal growth. |
| 3rd trimester | Prolonged use may cause neonatal adrenal suppression. Monitor neonate for signs of adrenal insufficiency. |
Clinical note
Comprehensive clinical and safety monograph for TRIESENCE (TRIESENCE).
| Placental transfer | Corticosteroids cross the placenta; triamcinolone acetonide is a fluorinated steroid with relatively high placental transfer. Degree depends on dose and route; systemic administration leads to significant fetal exposure. |
| Breastfeeding | Systemic corticosteroids are excreted into breast milk in low amounts. At maternal doses up to 80 mg/day prednisone equivalent, levels are low and unlikely to affect the infant. However, with high doses or prolonged use, monitor infant for growth and adrenal suppression. TRIESENCE (triamcinolone acetonide) is a depot formulation; local injection minimizes systemic exposure. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to triamcinolone acetonide or any componentSystemic fungal infectionIntravitreal injection in patients with active ocular infections or glaucomaUncontrolled hypertension or diabetes mellitus (for high-dose systemic use)
| Precautions | Increased intraocular pressure, glaucoma, optic nerve damage, posterior subcapsular cataract formation, Exacerbation of ocular fungal, viral, or bacterial infections, Systemic corticosteroid effects with prolonged use, Adrenal suppression with high doses or prolonged therapy |
| Food/Dietary | No specific food interactions with TRIESENCE when administered via intravitreal injection. However, patients with diabetes should monitor blood glucose as corticosteroids may increase blood sugar levels. |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | Category C. First trimester: potential for cleft palate and cardiac defects based on animal studies; avoid use. Second and third trimesters: risk of intrauterine growth restriction, premature birth, and hypothalamic-pituitary-adrenal suppression in neonate. Use only if benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, and signs of infection. Fetal monitoring for growth restriction and adrenal insufficiency via ultrasound and nonstress testing. |
| Fertility Effects | May impair fertility by disrupting ovulation and menstrual cycle. Reversible upon discontinuation. |
| Clinical Pearls | TRIESENCE (triamcinolone acetonide injectable suspension) is a preservative-free formulation specifically for ophthalmic use. Must not be used for epidural or intrathecal administration due to risk of serious adverse events, including spinal cord infarction. Shake well before use; inspect for particulate matter or discoloration. Administer via intravitreal injection only; monitor intraocular pressure post-injection. Avoid concurrent use with live vaccines. |
| Patient Advice | This medication is injected directly into the eye by your ophthalmologist. · You may experience temporary blurred vision or floaters after injection. · Do not rub or press on your eye after the procedure. · Report any sudden vision loss, eye pain, or redness immediately. · Avoid strenuous activities and heavy lifting for 24 hours post-injection. · Use preservative-free artificial tears if dryness occurs; avoid other eye drops without doctor's approval. |